Literature DB >> 16861718

Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).

F Jakob1, F Marín, E Martín-Mola, D Torgerson, P Fardellone, S Adami, N C Thalassinos, D Sykes, J Melo-Gomes, C Chinn, T Nicholson, C Cooper.   

Abstract

BACKGROUND: Osteoporotic fractures remain a major public health problem. Currently available osteoporosis therapies significantly reduce the risk of fractures, but up to 50% of patients have an inadequate clinical outcome to therapy. AIM: To describe the clinical and quality of life (QOL) of a study population meeting a proposed definition of inadequate clinical outcome to osteoporosis therapy, recruited for the Observational Study of Severe Osteoporosis (OSSO).
DESIGN: Cross-sectional, observational study.
METHODS: Post-menopausal women with osteoporosis (n = 2314) were divided into Group 1 (those who had previously experienced a fragility fracture despite osteoporosis drug therapy for at least 12 months) (n = 1309, 57%), or Group 2 (those who had previously discontinued osteoporosis drug therapy due to non-compliance or side-effects) (n = 1005; 43%). Baseline clinical characteristics, quality of life (QOL) and osteoporosis/falls risk factors were analysed.
RESULTS: The overall population had low BMD (mean +/- SD T-score at lumbar spine -3.1 +/- 1.1), and risk factors for fracture such as previous fractures (67.8%), family history (15.1%), and prolonged glucocorticoid use (17.5%). QOL was poor: total QUALEFFO and EQ-5D scores were 46.8 +/- 18.7, and 0.50 +/- 0.33, respectively. Patients in Group 1 had higher age and body mass index, fewer hours of exercise, more previous fragility fractures and falls, and poorer QOL scores. DISCUSSION: Our definition of inadequate clinical outcome from osteoporosis drug therapy identifies a severe osteoporosis cohort with poor QOL and increased fracture risk. Using such a definition may lead to earlier recognition of inadequate clinical outcome to osteoporosis therapy, and improved interventions and results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861718     DOI: 10.1093/qjmed/hcl073

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  12 in total

1.  Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.

Authors:  C M McDonough; M R Grove; A D Elledge; A N A Tosteson
Journal:  Osteoporos Int       Date:  2011-04-12       Impact factor: 4.507

Review 2.  An updated systematic review of Health State Utility Values for osteoporosis related conditions.

Authors:  T Peasgood; K Herrmann; J A Kanis; J E Brazier
Journal:  Osteoporos Int       Date:  2009-03-07       Impact factor: 4.507

Review 3.  Quality of life in glaucoma and three other chronic diseases: a systematic literature review.

Authors:  Tim Mills; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).

Authors:  C Cooper; F Jakob; C Chinn; E Martin-Mola; P Fardellone; S Adami; N C Thalassinos; J Melo-Gomes; D Torgerson; A Gibson; F Marin
Journal:  Osteoporos Int       Date:  2007-10-30       Impact factor: 4.507

5.  A comparison of four different HRQoL generic questionnaire in five different patient groups.

Authors:  Lale Akbulut Aktekin; Filiz Eser; Simten Malhan; Ergun Öksüz; Dilek Keskin; Hatice Bodur
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

6.  Assessing response to osteoporosis therapy.

Authors:  E M Lewiecki; N B Watts
Journal:  Osteoporos Int       Date:  2008-06-11       Impact factor: 4.507

Review 7.  Inadequate responders to osteoporosis treatment: proposal for an operational definition.

Authors:  A Díez-Pérez; J González-Macías
Journal:  Osteoporos Int       Date:  2008-06-11       Impact factor: 4.507

8.  Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Authors:  E Cairoli; C Eller-Vainicher; F M Ulivieri; V V Zhukouskaya; S Palmieri; V Morelli; P Beck-Peccoz; I Chiodini
Journal:  Osteoporos Int       Date:  2014-02-08       Impact factor: 4.507

9.  Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications.

Authors:  Nick Freemantle; Cyrus Cooper; Christian Roux; Adolfo Díez-Pérez; Francis Guillemin; Bengt Jonsson; Sergio Ortolani; Johannes Pfeilschifter; Rob Horne; Shilpa Kakad; Susan Shepherd; Gerd Möller; Anne Marciniak; Luc Martinez
Journal:  Arch Osteoporos       Date:  2010-02-27       Impact factor: 2.617

10.  Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.

Authors:  Daniel Prieto-Alhambra; Aina Pagès-Castellà; Gemma Wallace; M Kassim Javaid; Andrew Judge; Xavier Nogués; Nigel K Arden; Cyrus Cooper; Adolfo Diez-Perez
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.